<DOC>
	<DOCNO>NCT01668173</DOCNO>
	<brief_summary>The purpose study test new drug call AUY922 . AUY922 FDA-approved . AUY922 new kind drug attack protein call HSP90 . HSP90 find normal cancer cell , investigator think important cancer cell . This study see AUY922 help people myelofibrosis , essential thrombocythemia polycythemia vera . This study also see AUY922 safe people myelofibrosis , essential thrombocythemia polycythemia vera . It find effect , good and/or bad , AUY922 patient disease . The researcher hope study help find good treatment primary myelofibrosis , essential thrombocythemia polycythemia vera .</brief_summary>
	<brief_title>HSP90 Inhibitor , AUY922 , Patients With Primary Myelofibrosis ( PMF ) , Post-Polycythemia Vera Myelofibrosis ( Post-PV MF ) , Post-Essential Thrombocythemia Myelofibrosis ( Post-ET MF ) , Refractory PV/ET</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Eligible patient must myeloproliferative neoplasm , specifically , primary myelofibrosis ( PMF ) , post polycythemia vera myelofibrosis ( postPV MF ) , post essential thrombocythemia myelofibrosis ( postET MF ) , PV/ET refractory hydroxyurea , phlebotomy anagrelide candidate standard therapy . ≥ 18 year age ECOG performance status 02 Acceptable prestudy organ function screen define : Hematologic : Absolute Neutrophil Count ( ANC ) ≥1.5x109/L Hemoglobin ( Hgb ) ≥ 8 g/dl ( may support transfusion ) Platelets ( plt ) ≥50x10^9/L Biochemistry : Potassium within normal limit Total calcium ( correct serum albumin ) phosphorus within normal limit Magnesium LLN correctable supplement Liver Kidney Functions AST/SGOT ALT/SGPT ≤ 1.5 x Upper Limit Normal ( ULN ) AP &gt; 2.5 X ULN Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 Serum bilirubin ≤ 1.5 x ULN ( Unless attributable Gilbert 's disease ) Serum creatinine ≤ 1.5 x ULN 24hour clearance ≥ 50 ml/min Negative serum pregnancy test . The serum pregnancy test must obtain prior first administration AUY922 ( ≤ 72 hour prior dose ) premenopausal woman woman &lt; 2 year onset menopause Patients previously receive JAK2 inhibitor eligible long drug 4 week . Ability understand willingness sign write informed consent document . Requiring ongoing therapy either G GMCSF , longacting version molecule Active medical condition infection cancer actively require treatment . Unresolved diarrhea ≥ CTCAE ( v4.02 ) grade 1 Prior antineoplastic treatment HSP90 HDAC inhibitor compound Patients undergone major surgery ≤ 2 week prior start study drug recover side effect therapy . Patient must ≥ 4 week since last chemotherapy treatment another systemic anticancer agent exception hydroxyurea . Hydroxyurea must discontinue least 48 hour prior initiation AUY922 . Patients must recover ( CTC ≤ 1 ) acute toxicity previous therapy ( exception alopecia ) . Active anticoagulation warfarin . Pregnant lactate woman Fertile woman childbearing potential ( WCBP ) use doublebarrier method contraception ( abstinence , oral contraceptive , intrauterine device barrier method contraception conjunction spermicidal jelly , surgically sterile ) . Male patient whose partner WCBP use doublebarrier method contraception . Impaired cardiac function , include one following : History ( family history ) long QT syndrome Mean QTc ≥ 450 msec baseline ECG History clinically manifest ischemic heart disease ( include myocardial infarction , stable unstable angina pectoris , coronary arteriography cardiac stress testing/imaging finding consistent infarction clinically significant coronary occlusion ) ≤ 6 month prior study start History heart failure leave ventricular ( LV ) dysfunction ( LVEF ≤ 45 % ) MUGA ECHO Clinically significant ECG abnormality include 1 following : left bundle branch block ( LBBB ) , right bundle branch block ( RBBB ) leave anterior hemiblock ( LAHB ) . ST segment elevation depression &gt; 1mm , 2nd ( Mobitz II ) , 3rd degree AV block . History presence atrial fibrillation , atrial flutter ventricular arrhythmia include ventricular tachycardia Torsades de Pointes Other clinically significant heart disease ( e.g . congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) Clinically significant rest bradycardia ( &lt; 50 beat per minute ) Patients currently receive treatment medication relative risk prolong QTcF interval induce Torsades de Pointes switch discontinue alternative drug prior commence AUY922 . Obligate use cardiac pacemaker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>HSP90 Inhibitor</keyword>
	<keyword>AUY922</keyword>
	<keyword>12-076</keyword>
</DOC>